Who
Jonathan E. Lim
Director
Company insider
Files Form 4 as: Director, Boundless Bio; Director, Maze Therapeutics; Chairman & CEO, Erasca; President, CEO & Director, Ignyta; Chief Executive Officer, Halozyme Therapeutics.
In numbers
- Trades disclosed
- 290
- Buys
- 12
- Sells
- 11
- Bought
- $5.2M
- Sold
- $3.0M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 5 Feb 2007
- Last trade
- 15 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 15 Jun 2026 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 15 Jun 2026filed 15 Jun 2026 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 29 Jan 2026filed 30 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 29 Jan 2026filed 30 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 23 Jun 2025filed 23 Jun 2025 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500,000 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —363,703 | filing |
| 3 Feb 2025filed 4 Feb 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,231,381 | filing |
| 3 Feb 2025filed 4 Feb 2025 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code C | —37,724 | filing |
| 3 Feb 2025filed 4 Feb 2025 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code C | —270,232 | filing |
| 9 Dec 2024filed 4 Feb 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,704 | filing |
| 9 Dec 2024filed 4 Feb 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,704 | filing |
| 9 Dec 2024filed 4 Feb 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,086 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —632,759 at $0.00 | filing |
| 20 Jun 2024filed 20 Jun 2024 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —6,610 at $0.00 | filing |
| 2 Apr 2024filed 4 Apr 2024 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —512,820 | filing |
| 2 Apr 2024filed 4 Apr 2024 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —5,128 | filing |
News
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in StockHALO · themarketsdaily.com · 9 Oct 2026Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysHALO · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Jonathan E. Lim; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.